Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Pancreatic Cancer: early-phase trial registry
101 of 283 indexed Pancreatic Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #33 of 28,707 conditions by registered trial count.
283 US clinical trials · 101 currently recruiting · #33 of 28,707 conditions by registered trial count
Pancreatic Cancer: 283 US clinical trials tracked, 101 recruiting.
Pancreatic Cancer is the subject of 283 registered US clinical trials on ClinicalTrials.gov, 101 of them currently open to new participants. 12 are in Phase 3-4 (later-stage) and 180 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 19 of these trials.
Enrollment posture brief
Registry condition pancreatic-cancer
OPEN 101 | RECR 36% | LATE 12 | EARLY 180 | RANK #33 | SPON 19
Volume-matched condition peers
Nearest open-share peer: Acute Respiratory Failure (36% recruiting · 14 trials)
Pancreatic Cancer lists 101 open slots (36% of 283 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Pancreatic Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Pancreatic Cancer recruits in line with its size-band peers.
101 of 283 indexed trials (35.7%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Pancreatic Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 19 of 283 trials (6.7%). 165 distinct sponsors appear on at least one study for this condition label.
-
Most Pancreatic Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 60 among the 279 trials that report a genuine target (sentinel values excluded). 170 of those (60.9%) plan for fewer than 100 participants.
-
Pancreatic Cancer research is mostly interventional.
237 interventional and 46 observational studies make up this index (83.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
283 total, page 5 of 6
Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer
Walid Shaib, MD
NCT02581215
Preoperative Rehabilitation During Neoadjuvant Therapy for Pancreatic Cancer
M.D. Anderson Cancer Center
NCT02295956
Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer
Yale University
NCT01523457
A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors
Pfizer
NCT04672460
Open-label Study of CS-1008 for Subjects With Untreated and Unresectable Pancreatic Cancer
Daiichi Sankyo
NCT00521404
Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer
National Cancer Institute (NCI)
NCT02311361
Vaccine Therapy Combined With Adjuvant Chemoradiotherapy in Treating Patients With Resected Stage I or Stage II Adenocarcinoma (Cancer) of the Pancreas
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT00084383
Vaccine Therapy, Cyclophosphamide, and Cetuximab in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT00305760
Gemcitabine Plus Oxaliplatin in Treating Patients With Refractory Locally Advanced or Metastatic Pancreatic Cancer
Alliance for Clinical Trials in Oncology
NCT00004190
Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02648282
LY3214996 +/- HCQ in Pancreatic Cancer
Kimberly Perez, MD
NCT04386057
Maytansinoid DM4-Conjugated Humanized Monoclonal Antibody huC242 in Treating Patients With Solid Tumors
ImmunoGen
NCT00352131
Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates
Academic Thoracic Oncology Medical Investigators Consortium
NCT02723331
ChemoRT With Adjuvant Chemo in Pancreatic Cancer (TARCEVA)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT00313560
A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01)
Celldex Therapeutics
NCT00709462
Gemcitabine and Capecitabine to Treat Patients With Advanced Pancreatic and Biliary Cancers
University of California, San Francisco
NCT00626158
LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors
PureTech
NCT04666688
Paclitaxel in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer
Theradex
NCT00111904
Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Mauna Kea Technologies
NCT01770405
R115777 in Treating Patients Who Have Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
NCT00005843
Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer
St. Vincent Medical Center - Los Angeles
NCT00002475
A Study to Collect Survival Data on Patients Previously Enrolled in Abraxane Pancreatic Cancer Study CA046.
Celgene
NCT02021500
Efficacy and Safety Study of LE-DT to Treat Locally Advanced or Metastatic Pancreatic Cancer
INSYS Therapeutics
NCT01186731
A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers
University of Michigan Rogel Cancer Center
NCT01661114
Sorafenib and Erlotinib in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery
Vanderbilt-Ingram Cancer Center
NCT00837876
A Study of Romidepsin (Depsipeptide) in Combination With Gemcitabine in Patients With Pancreatic and Other Advanced Solid Tumors
Celgene
NCT00379639
Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer That Did Not Respond to Previous Treatment With Gemcitabine
University of California, San Francisco
NCT00365144
Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas
M.D. Anderson Cancer Center
NCT01560949
Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to Surgery
Washington University School of Medicine
NCT05111353
Positron Emission Tomography Using [18F]-Labeled Substance P Antagonist Receptor Quantifier in Finding Disease in Patients With Pancreatic Cancer
National Institutes of Health Clinical Center (CC)
NCT00547612
Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer
Massachusetts General Hospital
NCT00366457
Tarceva and Capecitabine for Pancreatic Cancer
Dana-Farber Cancer Institute
NCT00125021
Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT in Patients With Locally Advanced Pancreatic Cancer
Washington University School of Medicine
NCT02283372
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Pancreatic Cancer That Cannot Be Removed by Surgery
Barbara Ann Karmanos Cancer Institute
NCT00004003
Administration as a Biological Adjuvant in Clinically-Staged, Resectable Pancreatic Adenocarcinoma
Edward Nelson
NCT00600002
Ablation of Unresectable Locally Advanced Pancreatic Cancer With Irreversible Electroporation (IRE) System
Holy Name Medical Center
NCT03614910
Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer
Vanderbilt-Ingram Cancer Center
NCT00987766
Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer
M.D. Anderson Cancer Center
NCT00068432
Trial Comparing EUS-guided Radiofrequency Ablation vs. EUS-guided Celiac Plexus Neurolysis
AdventHealth
NCT03152487
Gemcitabine and Radiation Therapy in Treating Patients With Cancer of the Pancreas
Wake Forest University Health Sciences
NCT00010166
BrUOG 295: Adjuvant FOLFOX-A For Resected Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
Brown University
NCT02022033
Calcitriol and Docetaxel in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer
OHSU Knight Cancer Institute
NCT00238199
Vaccine Therapy in Treating Patients With Resected or Locally Advanced Unresectable Pancreatic Cancer
University of Pittsburgh
NCT00008099
Endoscopic Biliary Co-axial Stent Placement Plus/Minus Use of Radiofrequency Ablation (RFA) for Clearance of Occluded Self Expandable Metal Stents (SEMS) in Patients With Distal Biliary Obstruction From Unresectable Biliary-pancreatic Malignancies
Memorial Sloan Kettering Cancer Center
NCT02340728
Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors
Georgetown University
NCT00003125
Secretin-Stimulated Magnetic Resonance Cholangiopancreatography (S-MRCP) in Pancreatic Patients
Elizabeth Hecht
NCT01094561
Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors
University of Colorado, Denver
NCT00551096
Study of Irinotecan Administered as a Continuous Infusion and Radiation Therapy for Upper Gastrointestinal Cancers
University of Southern California
NCT00183846
Abraxane Therapy in Patients With Pancreatic Cancer Who Failed First-Line Gemcitabine Therapy
University of Miami
NCT00691054
Cancer Coaching and Remote Education for Self-Empowerment (CARES) Study
H. Lee Moffitt Cancer Center and Research Institute
NCT06323291
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 114 |
| Phase 2 | 66 |
| Phase 3 | 10 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Pancreatic Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Pancreatic Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Pancreatic Cancer page
283 registered trials, 101 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 101 Pancreatic Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Pancreatic Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pancreatic Cancer condition card totals 283 registered trials; most-linked intervention Gemcitabine; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.